Press Releases
Clinical Data Validate Pioneering MeMed BV® Technology Improves Diagnosis of Pediatric Patients with Fever in the Emergency Department
Beckman Coulter and MeMed to Expand Access to Proven Host Immune Response Diagnostic Able to Distinguish Between Bacterial and Viral Infections
Tulsa ER & Hospital Adopts Trailblazing MeMed BV Test
Tucson ER & Hospital Adopts Trailblazing MeMed BV Test
Dr. Sergey Motov at Maimonides Medical Center to Host Webinar on Using MeMed BV® in the Emergency Department to Rapidly Differentiate Bacterial and Viral Infections
MeMed to Participate in Upcoming Conferences
MeMed to Host Webinar on Best Practice Clinical Use of MeMed BV® for Differentiating Viral from Bacterial Infections on April 28, 2022
MeMed to Host Integrated Symposium at the 32nd European Congress of Clinical Microbiology and Infectious Diseases Conference 23 April 2022
Fierce Medtech Names MeMed as One of its ‘Fierce 15’ Medical Technology Companies
MeMed Raises $93M to Accelerate Commercialization of its Host Immune-Response Product Portfolio
Clinical Data Published in Clinical Microbiology and Infection Support Use of MeMed’s Test in Reducing Antibiotic Overuse in Children
DiaSorin Launches LIAISON® MeMed BV®, the First High Throughput Blood Test to Differentiate Between Bacterial and Viral Infections, in Countries Accepting the CE Mark
FDA Clears First Technology to Distinguish between Bacterial and Viral Infections Using the Body’s Immune Response – The MeMed BV Test and MeMed Key Platform
MeMed Named a Finalist for AACC’s Disruptive Technology Award for MeMed COVID-19 Severity Test
MeMed’s COVID-19 Severity Test Receives CE Mark for Predicting Severe Outcomes in COVID-19 Patients
No results found.